You are here
P&T January 2017
President-elect Donald Trump campaigned on a promise to repeal Obamacare. We review what effect the incoming administration may have on U.S. health care policy.
The authors consider market stakeholder consolidation, market-driven efficiency demands, consumerism, and legal enforcement of patient rights related to access to appropriate drugs and posit how future P&T committees may approach these issues.
We examine key evidence against the standard cardiac function model and describe Branko Furst’s alternative model with its implications for therapy and further exploration.
A study finds that medication histories obtained by the pharmacy technician in a busy emergency department were much more accurate than those obtained by nurses.
We present some of the approaches to and challenges of the opioid crisis that emerged from thought-leaders at an Academy of Managed Care Pharmacy symposium.
We review key sessions from the Society for Immunotherapy of Cancer meeting.
We review key sessions from the American Heart Association annual meeting.
Survey reveals widespread health workplace intimidation
Plan to settle 340B disputes is itself the focus of a dispute
Approvals, new indications, regulatory activities, and more
Olaratumab (Lartruvo) for the treatment of soft tissue sarcoma; bezlotoxumab (Zinplava) for use with an antibiotic to reduce recurrence of C. difficile infection; and doxylamine succinate/pyridoxine hydrochloride (Bonjesta) for the treatment of nausea and vomiting during pregnancy
Zarxio (filgrastim-sndz), a biosimilar for the treatment of severe chronic neutropenia